Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT05236114 · ClinicalTrials.gov registry record

GEMINI-NSCLC: NSCLC Biomarker Study

A clinical trial of Non-Small Cell Lung Cancer, sponsored by Tempus AI.

Recruiting
Registry status
1,200
Enrollment target
20
Study locations

NCT05236114 is a study of Non-Small Cell Lung Cancer that is actively recruiting participants, run by Tempus AI. The registered enrollment target is 1,200 participants, above the 656-participant average among 449 other Non-Small Cell Lung Cancer trials with a reported enrollment target (83% higher). The trial reports 20 study locations across 11 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT05236114, a study of Non-Small Cell Lung Cancer, is actively recruiting participants, sponsored by Tempus AI.

RECRUITING
Registry status
1,200 participants
Enrollment target
20
Study locations

Study Summary

GEMINI NSCLC Study is a non-interventional study that will be collecting clinical and molecular health information from patients with NSCLC who will receive longitudinal blood collection in addition to their standard of care therapy and disease surveillance with the goals of identifying the molecular evolution of lung cancer with standard of care therapy, and determining the utility of ctDNA dynamics to predict risk of recurrence and therapeutic outcomes.

Conditions Studied

Non-Small Cell Lung Cancer

Interventions

  • OTHER Observation

Study Locations (20)

Illinois

  • Southern Illinois Hospital Services - Carterville
  • Cancer Care Specialists of Illinois - Decatur
  • Northwestern University - Evanston
  • Hope and Healing Cancer Services - Hinsdale
  • OSF Saint Anthony Medical Center - Rockford

California

  • MemorialCare - Fountain Valley
  • Cancer and Blood Specialty Clinic - Los Alamitos
  • UCLA - Los Angeles

Florida

  • Clermont Oncology Center - Clermont
  • Woodlands Medical Specialists - Pensacola

Georgia

  • Morehouse School of Medicine (MSM) - Atlanta
  • Piedmont Healthcare - Atlanta

Maryland

  • University of Maryland - Baltimore
  • Johns Hopkins University - Baltimore

Alabama

  • Alabama Oncology - Birmingham

Arkansas

  • Mercy Clinic Oncology - Fort Smith - Fort Smith

Connecticut

  • Eastern CT and Hematology and Oncology Associates - Norwich

Trial Details

FieldValue
Enrollment Target 1,200 participants
Start Date 2022-06-22
Est. Completion 2029-06

Sponsor

Tempus AI

13 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT05236114

The ClinicalTrials.gov registry entry for NCT05236114 describes a study currently listed as recruiting, categorized as an unspecified phase. The registered enrollment target is 1,200 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 656-participant average among 449 other Non-Small Cell Lung Cancer trials with a reported enrollment target (83% higher). The listed sponsor is Tempus AI, which has 13 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Non-Small Cell Lung Cancer appearing as the primary indexed condition, and to 1 intervention - of which Observation is the first listed.

NCT05236114 reports 20 study locations spanning 11 distinct geographic areas - top geographies include Illinois, California, Florida.

Frequently Asked Questions

What is clinical trial NCT05236114 about?

NCT05236114 is a clinical study titled "GEMINI-NSCLC: NSCLC Biomarker Study". GEMINI NSCLC Study is a non-interventional study that will be collecting clinical and molecular health information from patients with NSCLC who will receive longitudinal blood collection in addition to their standard of care therapy and disease surveillance with the goals of identifying the molecula...

What is the current status of trial NCT05236114?

This trial is currently recruiting. The enrollment target is 1,200 participants. The study started on 2022-06-22. Estimated completion is 2029-06.

What conditions does trial NCT05236114 study?

This clinical trial studies the following conditions: Non-Small Cell Lung Cancer.

What interventions are being tested in trial NCT05236114?

The interventions under investigation include: Observation (OTHER).

Who is sponsoring clinical trial NCT05236114?

This trial is sponsored by Tempus AI, which has 13 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT05236114 being conducted?

This trial has 20 study locations across Alabama, Arkansas, California, Connecticut, Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Non-Small Cell Lung Cancer

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Non-Small Cell Lung Cancer

All registered trials for this condition

Alabama

All trials with a study site in Alabama

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.